Pyramidion Technology Group, Inc. (OTC: ‘PYTG’) Gains Surgical Neurophysiologist as an Active Board Member

WESTON, Florida, September 20, 2018 /PRNewswire/ — Pyramidion Technology Group, Inc. (OTC:PYTG) reveals new addition of a Board Certified Neurophysiologic Intraoperative Monitor (CNIM), to the company’s advisory board.


Antonio Sama, CNIM, is a medical professional specializing in the Central Nervous System (CNS) whose crucial role in the operating room is to map out patients’ nerve routes for surgeons during surgery. This real-time data of nerve-route mapping aids physicians in detecting injuries to the CNS which has been known to reduce the risk of post-surgical debilitating neurological deficits such as muscle weakness, paralysis, hearing loss, as well as other neurological body functions.


PYTG’s advisory board is comprised of experts in medical sciences including a board-certified cardiologist, Dr. Mark Sabbota, Dr. David M. Feldbaum, Fellow, American College of Surgeons (FACS), among others who are leaders in, and advocates of, the wise implementation of what has historically been considered alternative medicine such as products containing Cannabidiol (CBD) oil.


CEO of PYTG, Carlos Hurtado explains, “We are at the forefront of changing peoples’ views on CBD containing products and shifting from viewing these goods as ‘alternative medicines’ to primary sources of relief-providing courses of action. In order for us to effectively move forward, we must bring in the experts to guide our company, other medical professionals, and clients on the most optimal ways to utilize CBD containing products.”


Antonio Sama, whose area of expertise lies in the Central Nervous System explains, “I am an advocate of hemp-based products such as those containing CBD because I continually witness remarkable improvement, alleviation, and symptomatic relief from the side-effects of potent, potentially toxic, medications prescribed to control my wife’s chronic ailment: Crohn’s disease and its rheumatologic manifestations.”


Crohn’s disease in an inflammatory bowel disease (IBD) causing inflammation of the digestive track which can also lead to abdominal pain, diarrhea, fatigue, and consequently weight loss and malnutrition caused by the lack of proper vitamin and mineral absorption. Crohn’s disease is reported to be both debilitating and potentially life threatening and there is currently no known cure.


Sama continues on to say that, “I anticipated that these natural remedies were going to work and my pre-conceived notions of their effectiveness have converted into a reality by my first-hand experience witnessing their positive effects on my wife’s life as well as mine. In addition to producing the desired results, these products are available at a fraction of the cost and with less aggravation than pharmaceutical alternatives. I am excited for the opportunity to help take LeafyWell’s products into my own hands and work to educate my medical professional colleagues on the benefits and results.”


Sama’s experience both in the medical profession and as a first-hand witness of the positive role that CBD can play, demonstrate promise in decision making as the company seeks to design quality products in accessible forms to consumers. The board member composition will play a key role in how the products are formulated as well as their delivery methods.


Carlos Hurtado, CEO of PYTG continues to explain that, “These folks are the experts in the human body as well as experts in the needs of patients. They will guide us to produce the formulations and delivery methods that make the most sense. In some cases, for some physical conditions, edibles (edible products containing CBD oils such as gummy candies or cookies) may be the best option and for others, it might be an oil. This is precisely one of the many reasons why we seek the input from these medical professionals. These medical professionals also play instrumental roles in educating their colleagues and patients to the best options available.”


About Pyramidion Technology Group, Inc 

Pyramidion Technology Group, Inc. (“PYTG” or the “Company”) is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.


Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships,


marketing synergies and distribution methods that enable combined companies to provide a wide variety of unique and complete solutions, services and necessities to consumers. We believe our overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.


For more information on PYTG, please visit the Company’s website at

To be added to the Company investor email list, please email with PYTG in the subject line.



This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance


on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.


For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at


Phone: +1-954-329-2205

SOURCE Pyramidion Technology Group, Inc